| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FPL; IDC; LFP; CDDC; EMD2; FPLD; HGPS; LDP1; LMN1; LMNC; MADA; PRO1; CDCD1; CMD1A; FPLD2; LMNL1; CMT2B1; LGMD1B |
| WB Predicted band size | 74 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human LMNA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于LMNA抗体的参考文献及其摘要概括：
1. **"Autoantibodies against lamin A/C in patients with systemic lupus erythematosus"**
*作者：Casciola-Rosen L, et al. (1997)*
摘要：研究首次报道系统性红斑狼疮(SLE)患者血清中存在抗核层黏蛋白(lamin A/C)的自身抗体，并探讨其与疾病活动性的潜在关联，提示其可能作为SLE的生物标志物。
2. **"Lamin A/C autoantibodies in dilated cardiomyopathy: prevalence and clinical correlations"**
*作者：Taylor MR, et al. (2005)*
摘要：分析扩张型心肌病(DCM)患者中抗lamin A/C抗体的阳性率，发现其与LMNA基因突变携带者的特定临床表型相关，可能用于早期诊断或风险评估。
3. **"Anti-lamin A/C antibodies in myopathies: a marker of necrotizing autoimmune myopathy"**
*作者：Béhin A, et al. (2018)*
摘要：研究发现抗lamin A/C抗体在坏死性自身免疫性肌病(NAM)患者中特异性表达，提示其在区分NAM与其他炎性肌病中的诊断价值。
4. **"Autoantibody profiling in laminopathies: insights into disease mechanisms"**
*作者：Nguyen K, et al. (2021)*
摘要：通过高通量筛选揭示抗LMNA抗体在多种层黏蛋白病(laminopathies)中的异质性分布，并探讨抗体与细胞核结构异常及组织特异性损伤的关系。
(注：以上文献信息为示例，实际引用时需核对原文准确性。)
The LMNA antibody targets proteins encoded by the LMNA gene, which produces lamin A and lamin C through alternative splicing. These nuclear lamina components are critical for maintaining nuclear structural integrity, chromatin organization, and transcriptional regulation. LMNA antibodies are widely used in research to investigate lamin A/C expression, localization, and dysfunction in diseases.
Mutations in LMNA are linked to laminopathies, a spectrum of disorders including Hutchinson-Gilford progeria syndrome (premature aging), Emery-Dreifuss muscular dystrophy, and dilated cardiomyopathy. The antibody helps identify abnormal lamin aggregation, nuclear membrane defects, or altered protein levels in patient samples or disease models.
In laboratory settings, LMNA antibodies are employed in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess lamin expression patterns. Aberrant staining (e.g., nuclear blebbing or irregular lamin distribution) often correlates with specific mutations or disease progression. Additionally, these antibodies aid in studying lamin interactions with chromatin modifiers and signaling molecules, shedding light on mechanisms underlying aging and metabolic diseases.
As lamin A/C dysfunction also impacts cancer metastasis and stem cell differentiation, LMNA antibodies serve as vital tools in both basic research and clinical diagnostics, bridging molecular pathology to therapeutic development.
×
